Duchenne MD Therapy Breakthrough

In what will be great news to families living with Duchenne Muscular Dystrophy, the first therapy specifically developed to treat DMD has been approved by the US Food and Drug Administration.

 

The U.S. Food and Drug Administration has approved Sarepta Therapeutics’ therapy Exondys 51 (eteplirsen) as a treatment for Duchenne muscular dystrophy patients.

 

The ground-breakling drug was developed by Perth-based researchers.

 

CLICK HERE FOR MORE INFORMATION